Zolgensma® (onasemnogene abeparvovec-xioi)
| Full Name | Zolgensma® (onasemnogene abeparvovec-xioi) |
| Drug | Zolgensma |
| Manufacturer | Novartis Gene Therapy |
| Route of Administration | Intravenous |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene |
| Disease | Spinal Muscular Atrophy (SMA) |
| Therapeutic Area | Neurology; Cell & Gene Therapy |
| Enrollment Form | Enrollment Form |
| Phone Number | 800-697-5048 |
| Fax Number | 877-471-5704 |
| Website | zolgensma.com |
| Patient Resources | Cure SMA and Muscular Dystrophy Association |